Human neutrophil alpha-defensins induce formation of fibrinogen and thrombospondin-1 amyloid-like structures and activate platelets via glycoprotein IIb/IIIa

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 4, 2012, Pages 647-661

  Horn, M ^a   Bertling, A ^a   Brodde, M F ^a   Muller A ^a   Roth, J ^b   Van Aken, H ^a   Jurk, K ^a   Heilmann, C ^a   Peters, G ^a   Kehrel, B E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Host defense; Neutrophil defensins; Platelets; Thrombosis

Indexed keywords

ALPHA 2 MACROGLOBULIN; ALPHA DEFENSIN; CASPASE 3; CD40 LIGAND; FIBRINOGEN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; GLYCOSAMINOGLYCAN; HEPARIN; HEPARINOID; HIRUDIN; HUMAN NEUTROPHIL ALPHA DEFENSIN; PROCOAGULANT; SERINE PROTEINASE INHIBITOR; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONFOCAL MICROSCOPY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; MEMBRANE MICROPARTICLE; MITOCHONDRIAL MEMBRANE; NEUTROPHIL; NORMAL HUMAN; PATHOPHYSIOLOGY; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROTEIN BINDING; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; THROMBOSIS; VASCULAR DISEASE;

ALPHA-DEFENSINS; AMYLOID; ANTITHROMBINS; APOPTOSIS; BLOOD PLATELETS; CASPASE 3; CELL DEGRANULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; INFLAMMATION; INTEGRIN ALPHA2; INTEGRIN BETA3; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, CONFOCAL; NEUTROPHIL ACTIVATION; NEUTROPHILS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SERPINS; THROMBOSIS; THROMBOSPONDIN 1; TIME FACTORS;

EID: 84859169216     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04640.x     Document Type: Article

References (78)

1. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005; 31: 381-92.
2. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103: 1718-20.
3. Clifford DP, Repine JE. Hydrogen peroxide mediated killing of bacteria. Mol Cell Biochem 1982; 49: 143-9.
4. Hill CP, Yee J, Selsted ME, Eisenberg D. Crystal structure of defensin HNP-3, an amphiphilic dimer: mechanisms of membrane permeabilization. Science 1991; 251: 1481-5.
5. Zhao C, Wang I, Lehrer RI. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett 1996; 396: 319-22.
6. Rodriguez-Garcia M, Oliva H, Climent N, Garcia F, Gatell JM, Gallart T. Human immature monocyte-derived dendritic cells produce and secrete alpha-defensins 1-3. J Leukoc Biol 2007; 82: 1143-6.
7. Ganz T, Lehrer RI. Defensins. Curr Opin Immunol 1994; 6: 584-9.
8. Ganz T. Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes. Infect Immun 1987; 55: 568-71.
9. Panyutich AV, Panyutich EA, Krapivin VA, Baturevich EA, Ganz T. Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. J Lab Clin Med 1993; 122: 202-7.
10. Ganz T, Weiss J. Antimicrobial peptides of phagocytes and epithelia. Semin Hematol 1997; 34: 343-54.
11. Lichtenstein A. Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J Clin Invest 1991; 88: 93-100.
12. Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000; 68: 9-14.
13. Murphy CJ, Foster BA, Mannis MJ, Selsted ME, Reid TW. Defensins are mitogenic for epithelial cells and fibroblasts. J Cell Physiol 1993; 155: 408-13.
14. Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov II, Petratchenko EV, Voitenok NN. Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine Netw 2000; 11: 257-66.
15. Chignard M, Selak MA, Smith JB. Direct evidence for the existence of a neutrophil-derived platelet activator (neutrophilin). Proc Natl Acad Sci U S A 1986; 83: 8609-13.
16. Kehrel BE, Kronenberg A, Schwippert B, Niesing-Bresch D, Niehues U, Tschöpe D, van de Loo J, Clemetson KJ. Thrombospondin binds normally to glycoprotein IIIb deficient platelets. Biochem Biophys Res Commun 1991; 179: 985-91.
17. Xia Z, Wong T, Liu Q, Kasirer-Friede A, Brown E, Frojmovic MM. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol 1996; 93: 204-14.
18. Kehrel B, Wierwille S, Clemetson KJ, Anders O, Steiner M, Knight CG, Farndale RW, Okuma M, Barnes MJ. Glycoprotein VI is a major collagen receptor for platelet activation: It recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von willebrand factor do not. Blood 1998; 91: 491-9.
19. Jurk K, Clemetson KJ, de Groot PG, Brodde MF, Steiner M, Savion N, Varon D, Sixma JJ, Van Aken H, Kehrel BE. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein ib (GPIb): an alternative/backup mechanism to von willebrand factor. FASEB J 2003; 17: 1490-2.
20. Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000; 96: 2469-78.
21. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9.
22. Nofer JR, Herminghaus G, Brodde M, Morgenstern E, Rust S, Engel T, Seedorf U, Assmann G, Bluethmann H, Kehrel BE. Impaired platelet activation in familial high density lipoprotein deficiency (tangier disease). J Biol Chem 2004; 279: 34032-7.
23. Lahav J, Jurk K, Hess O, Barnes MJ, Farndale RW, Luboshitz J, Kehrel BE. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood 2002; 100: 2472-8.
24. Dormann D, Kardoeus J, Zimmermann RE, Kehrel B. Flow cytometric analysis of agonist-induced annexin V, factor va and factor xa binding to human platelets. Platelets 1998; 9: 171-7.
25. Jurk K, Jahn UR, Van Aken H, Schriek C, Droste DW, Ritter MA, Bernd Ringelstein E, Kehrel BE. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost 2004; 91: 334-44.
26. Verhoeven AJ, Verhaar R, Gouwerok EG, de Korte D. The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality. Transfusion 2005; 45: 82-9.
27. Klunk WE, Jacob RF, Mason RP. Quantifying amyloid beta-peptide (abeta) aggregation using the congo red-abeta (CR-abeta) spectrophotometric assay. Anal Biochem 1999; 266: 66-76.
28. Sinha B, Francois PP, Nusse O, Foti M, Hartford OM, Vaudaux P, Foster TJ, Lew DP, Herrmann M, Krause KH. Fibronectin-binding protein acts as Staphylococcus aureus invasin via fibronectin bridging to integrin alpha5beta1. Cell Microbiol 1999; 1: 101-17.
29. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54: 669-77.
30. Singbartl K, Forlow SB, Ley K. Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. FASEB J 2001; 15: 2337-44.
31. McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997; 100(11 Suppl): S97-103.
32. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-57.
33. Vanags DM, Orrenius S, Aguilar-Santelises M. Alterations in bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. Br J Haematol 1997; 99: 824-31.
34. Wolf BB, Goldstein JC, Stennicke HR, Beere H, Amarante-Mendes GP, Salvesen GS, Green DR. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood 1999; 94: 1683-92.
35. Shcherbina A, Remold-O'Donnell E. Role of caspase in a subset of human platelet activation responses. Blood 1999; 93: 4222-31.
36. Leytin V, Allen DJ, Mykhaylov S, Lyubimov E, Freedman J. Thrombin-triggered platelet apoptosis. J Thromb Haemost 2006; 4: 2656-63.
37. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
38. Yeaman MR, Bayer AS. Antimicrobial peptides from platelets. Drug Resist Updat 1999; 2: 116-26.
39. Liu CY, Lin HC, Yu CT, Lin SM, Lee KY, Chen HC, Chou CL, Huang CD, Chou PC, Liu WT, Wang CH, Kuo HP. The concentration-dependent chemokine release and pro-apoptotic effects of neutrophil-derived alpha-defensin-1 on human bronchial and alveolar epithelial cells. Life Sci 2007; 80: 749-58.
40. Aarbiou J, Tjabringa GS, Verhoosel RM, Ninaber DK, White SR, Peltenburg LT, Rabe KF, Hiemstra PS. Mechanisms of cell death induced by the neutrophil antimicrobial peptides alpha-defensins and LL-37. Inflamm Res 2006; 55: 119-27.
41. Wimley WC, Selsted ME, White SH. Interactions between human defensins and lipid bilayers: evidence for formation of multimeric pores. Protein Sci 1994; 3: 1362-73.
42. Zhang Y, Lu W, Hong M. The membrane-bound structure and topology of a human alpha-defensin indicate a dimer pore mechanism for membrane disruption. Biochemistry 2010; 49: 9770-82.
43. Madison MN, Kleshchenko YY, Nde PN, Simmons KJ, Lima MF, Villalta F. Human defensin alpha-1 causes Trypanosoma cruzi membrane pore formation and induces DNA fragmentation, which leads to trypanosome destruction. Infect Immun 2007; 75: 4780-91.
44. Harrison RS, Sharpe PC, Singh Y, Fairlie DP. Amyloid peptides and proteins in review. Rev Physiol Biochem Pharmacol 2007; 159: 1-77.
45. McDonald JF, Dimitry JM, Frazier WA. An amyloid-like C-terminal domain of thrombospondin-1 displays CD47 agonist activity requiring both VVM motifs. Biochemistry 2003; 42: 10001-11.
46. Gebbink MF. Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis. J Thromb Haemost 2011; 9(Suppl. 1): 174-81.
47. Stefani M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta 2004; 1739: 5-25.
48. Herczenik E, Bouma B, Korporaal SJ, Strangi R, Zeng Q, Gros P, Van Eck M, Van Berkel TJ, Gebbink MF, Akkerman JW. Activation of human platelets by misfolded proteins. Arterioscler Thromb Vasc Biol 2007; 27: 1657-65.
49. Ogawa T, Sugidachi A, Otsuguro K, Isobe T, Asai F. Platelet alpha-granule secretion and its modification by SC-57101A, a GPIIb/IIIa antagonist. Biochem Pharmacol 2002; 63: 1911-8.
50. Naimushin YA, Mazurov AV. Role of glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) in stimulation of secretion from platelet granules. Biochemistry (Mosc) 2003; 68: 209-16.
51. Buensuceso CS, Obergfell A, Soriani A, Eto K, Kiosses WB, Arias-Salgado EG, Kawakami T, Shattil SJ. Regulation of outside-in signaling in platelets by integrin-associated protein kinase C beta. J Biol Chem 2005; 280: 644-53.
52. Obergfell A, Eto K, Mocsai A, Buensuceso C, Moores SL, Brugge JS, Lowell CA, Shattil SJ. Coordinate interactions of csk, src, and syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. J Cell Biol 2002; 157: 265-75.
53. Woodside DG, Obergfell A, Leng L, Wilsbacher JL, Miranti CK, Brugge JS, Shattil SJ, Ginsberg MH. Activation of syk protein tyrosine kinase through interaction with integrin beta cytoplasmic domains. Curr Biol 2001; 11: 1799-804.
54. Rennemeier C, Hammerschmidt S, Niemann S, Inamura S, Zahringer U, Kehrel BE. Thrombospondin-1 promotes cellular adherence of gram-positive pathogens via recognition of peptidoglycan. FASEB J 2007; 21: 3118-32.
55. Niemann S, Kehrel BE, Heilmann C, Rennemeier C, Peters G, Hammerschmidt S. Pneumococcal association to platelets is mediated by soluble fibrin and supported by thrombospondin-1. Thromb Haemost 2009; 102: 735-42.
56. Niemann S, Spehr N, Van Aken H, Morgenstern E, Peters G, Herrmann M, Kehrel BE. Soluble fibrin is the main mediator of Staphylococcus aureus adhesion to platelets. Circulation 2004; 110: 193-200.
57. Ashmarin IP, Tkachenko SB, Rud'ko IA, Korneva EA, Kokriakov VN, Kubatiev AA. Effect of defensin on platelet functional activity. Biull Eksp Biol Med 1993; 115: 23-5.
58. 2+ in platelets. Biull Eksp Biol Med 1994; 118: 600-3.
59. Liapina LA, Kondashevskaia MV, Kokriakov VN, Shamova OV. Interaction of heparin with defensin, a nonenzymatic cationic protein from neutrophils. Vopr Med Khim 1992; 38: 39-42.
60. Panyutich AV, Hiemstra PS, van Wetering S, Ganz T. Human neutrophil defensin and serpins form complexes and inactivate each other. Am J Respir Cell Mol Biol 1995; 12: 351-7.
61. Panyutich A, Ganz T. Activated alpha 2-macroglobulin is a principal defensin-binding protein. Am J Respir Cell Mol Biol 1991; 5: 101-6.
62. Stakisaitis D, Basys V, Benetis R. Does alpha-1-proteinase inhibitor play a protective role in coronary atherosclerosis? Med Sci Monit 2001; 7: 701-11.
63. Conard J, Brosstad F, Lie Larsen M, Samama M, Abildgaard U. Molar antithrombin concentration in normal human plasma. Haemostasis 1983; 13: 363-8.
64. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989; 264: 11539-42.
65. Hesselvik JF, Blomback M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989; 17: 724-33.
66. Bagge L, Haglund O, Wallin R, Borg T, Modig J. Differences in coagulation and fibrinolysis after traumatic and septic shock in man. Scand J Clin Lab Invest 1989; 49: 63-72.
67. Ambrus JL, Ambrus CM. Changes in the fibrinolysin system in infantile and adult respiratory distress syndrome (ARDS), caused by trauma and/or septic shock in patients and in experimental animals. J Med 1990; 21: 67-84.
68. Carvalho AC, DeMarinis S, Scott CF, Silver LD, Schmaier AH, Colman RW. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J Lab Clin Med 1988; 112: 270-7.
69. Sheth SB, Carvalho AC. Protein S and C alterations in acutely ill patients. Am J Hematol 1991; 36: 14-9.
70. Fourrier F, Lestavel P, Chopin C, Marey A, Goudemand J, Rime A, Mangalaboyi J. Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 1990; 16: 121-4.
71. de Boer JP, Creasey AA, Chang A, Abbink JJ, Roem D, Eerenberg AJ, Hack CE, Taylor FB Jr. Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model. Infect Immun 1993; 61: 5035-43.
72. Eisenhauer PB, Lehrer RI. Mouse neutrophils lack defensins. Infect Immun 1992; 60: 3446-7.
73. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002; 288: 2724-31.
74. Wimmer ML, Sandmann-Strupp R, Saikku P, Haberl RL. Association of chlamydial infection with cerebrovascular disease. Stroke 1996; 27: 2207-10.
75. Cook PJ, Honeybourne D, Lip GY, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the west birmingham stroke project. Stroke 1998; 29: 404-10.
76. Elkind MS, Tondella ML, Feikin DR, Fields BS, Homma S, Di Tullio MR. Seropositivity to Chlamydia pneumoniae is associated with risk of first ischemic stroke. Stroke 2006; 37: 790-5.
77. Ridker PM, Hennekens CH, Stampfer MJ, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation 1998; 98: 2796-9.
78. Heuschmann PU, Neureiter D, Gesslein M, Craiovan B, Maass M, Faller G, Beck G, Neundoerfer B, Kolominsky-Rabas PL. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: results from a population-based case-control study. Stroke 2001; 32: 2253-8.